Intellia Therapeutics is a cash-burning gene editing company with two high-concentration pipeline programs — lonvo-z for HAE and nex-z for ATTR amyloidosis — where short interest of 44% reflects deep skepticism, but a perfect 4-quarter earnings beat streak and 78% analyst upside indicate institutional believers see a path to significant value creation.
Thesis pillars
- Dual Pipeline Concentration Risk↓Deteriorating
- Extreme Short Interest Skepticism↓Deteriorating
- Cash Burn Below Quality Floor→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026· older than 90 days
Intellia Therapeutics, Inc. (NTLA) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $12.31: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10 and A.R:R 4.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 40%; Below-average business quality; Below long-term trend.
Intellia Therapeutics is a pre-commercial CRISPR gene editing company with two Phase 3 programs: lonvo-z for hereditary angioedema (HAE) and nex-z for ATTR amyloidosis, both designed as one-time in vivo treatments. The planned U.S. commercial launch for lonvo-z targets the first... Read more
Sell if holding. Engine safety override at $12.31: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10 and A.R:R 4.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 40%; Below-average business quality; Below long-term trend. Chart setup: RSI 59 mid-range, Bollinger mid-band. Score 3.7/10, high confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About Intellia Therapeutics, Inc.
About Intellia Therapeutics, Inc.
Intellia Therapeutics is advancing two in vivo CRISPR therapies in Phase 3: lonvo-z for hereditary angioedema (HAE), with topline data from the 80-patient HAELO study expected mid-2026 and BLA submission planned for the second half of 2026; and nex-z for ATTR amyloidosis, with the MAGNITUDE Phase 3 trial (more than 650 enrolled patients for ATTR-CM) on FDA clinical hold since October 29, 2025, while the MAGNITUDE-2 study for ATTRv-PN had its hold lifted in January 2026 with enrollment expected to complete in the second half of 2026.
Intellia generates pre-commercial revenue primarily through collaboration arrangements. Nex-z is co-developed with Regeneron Pharmaceuticals, which shares approximately 25% of worldwide development costs and commercial profits under the ATTR co-development and co-promotion agreement; Intellia serves as the clinical and commercial lead. Under the 2016 Regeneron Agreement, Intellia is eligible for up to $320 million per in vivo target in development and commercial milestone payments plus mid-single-digit royalties on future sales. Lonvo-z is wholly owned. Additional revenue flows from licensing arrangements with AvenCell Therapeutics (ex vivo CAR-T programs) and Kyverna Therapeutics (allogeneic CD19 CAR-T for autoimmune disease). No genome editing in vivo therapy has been approved in the U.S., EU, or other key jurisdictions, and neither lonvo-z nor nex-z has received marketing authorization.
Show full overview
The company's near-term value depends on two binary clinical readouts. Lonvo-z's HAELO Phase 3 primary endpoint — HAE attacks from week 5 through week 28 — is due mid-2026; a missed endpoint would eliminate the planned H1 2027 commercial launch and BLA submission timeline. For nex-z, the MAGNITUDE Phase 3 trial for ATTR-CM remains on FDA clinical hold following a Grade 4 liver injury and patient death reported in October 2025; Intellia has stated it cannot predict when the MAGNITUDE trial may resume, and failure to resolve the hold could prevent commercialization of the ATTR-CM indication, the larger of the two ATTR patient populations.
See also: Healthcare · Biotechnology
From Intellia Therapeutics, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Nov 4, 2026Recent Developments — Intellia Therapeutics, Inc.
Latest news
- NEWS Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial — fiscal.ai Nov 4, 2026 positive
- NEWS Intellia Therapeutics Completed Participant Enrollment In Its MAGNITUDE-2 Study Of ATTRv-PN — benzinga Nov 4, 2026 positive
- NEWS Intellia Therapeutics Announces Upcoming Clinical Data Presentations for Nexiguran Ziclumeran — fiscal.ai Nov 3, 2026 neutral
- NEWS Intellia Therapeutics Announces Upcoming Investor Event and ACAAI Presentations — fiscal.ai Oct 29, 2026 neutral
- NEWS Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — fiscal.ai Oct 28, 2026 neutral
Latest item Nov 4, 2026 · Generated 2026-11-05T11:49:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinelonvo-z (HAE)10-K Item 1: 'Lonvo-z and nex-z are currently in Phase 3 clinical development, and we are preparing for the planned commercial launch of lonvo-z in the first half of 2027'
- HIGHpipelinenex-z (ATTR amyloidosis)10-K Item 1A: 'the FDA placed a clinical hold on the IND applications for the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials ... a patient who was dosed with nex-z in the MAGNITUDE trial'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Revenue shrinking — -46.2% YoY. Growth thesis broken unless recovery story develops.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $12.31: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10 and A.R:R 4.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 40%; Below-average business quality; Below long-term trend. Chart setup: RSI 59 mid-range, Bollinger mid-band. Prior stop was $11.45. Score 3.7/10, high confidence.
Analyst target: $20.80 (+69.0% upside). Prior stop was $11.45. Stop-loss: $11.45.
Concentration risk — Pipeline: lonvo-z (HAE); Concentration risk — Pipeline: nex-z (ATTR amyloidosis); Quality below floor (1.7 < 4.0).
Intellia Therapeutics, Inc. trades at a P/E of N/A (forward -4.8). TrendMatrix value score: 5.4/10. Verdict: Sell.
25 analysts rate NTLA, with a consensus score of 3.5/5. 18 analysts publish price targets averaging $23.
What does Intellia Therapeutics, Inc. do?Intellia Therapeutics is a pre-commercial CRISPR gene editing company with two Phase 3 programs: lonvo-z for hereditary...
Intellia Therapeutics is a pre-commercial CRISPR gene editing company with two Phase 3 programs: lonvo-z for hereditary angioedema (HAE) and nex-z for ATTR amyloidosis, both designed as one-time in vivo treatments. The planned U.S. commercial launch for lonvo-z targets the first half of 2027; revenue currently comes from collaboration arrangements including a cost- and profit-sharing agreement with Regeneron for nex-z.